Arca
Skip to content

Malaria

Drug research and approvals for malaria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 58 studies of malaria are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 5 approved and 21 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 58
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 5
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 58 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

20 approved, 27 in phase 3, 15 in phase 2, 27 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Artesunate, Artemether, Lumefantrine, Amodiaquine, Pyrimethamine, Artenimol, Primaquine, Chloroquine, Mefloquine, Quinine, Atovaquone, Proguanil, Tafenoquine, Doxycycline anhydrous, Hydroxychloroquine, Quinidine, Halofantrine, Sulfadiazine, Artemotil, Artemisinin

Sulfadoxine
Phase 3 Dihydropteroate synthetase inhibitor
Piperaquine
Phase 3 Ferriprotoporphyrin IX inhibitor
Rabies vaccine
Phase 3 Biological vaccine - induces immune response
Ivermectin
Phase 3 Glutamate-gated chloride channel modulator
Dapsone
Phase 3 Dihydropteroate synthase 1 inhibitor
Azithromycin
Phase 3 Bacterial 70S ribosome inhibitor
Fosmidomycin
Phase 3 1-deoxy-D-xylulose 5-phosphate reductoisomerase, apicoplastic inhibitor
Yellow fever vaccine
Phase 3 Biological vaccine - induces immune response
Retinol
Phase 3
Acetaminophen
Phase 3 Cyclooxygenase inhibitor
Cisplatin
Phase 3 DNA inhibitor
Cytarabine
Phase 3 DNA inhibitor
Prasterone
Phase 3 Unknown
Dexamethasone
Phase 3 Glucocorticoid receptor agonist
Albendazole
Phase 3 Tubulin inhibitor
Sulfalene
Phase 3 Bacterial dihydropteroate synthase inhibitor
Sulfamethoxazole
Phase 3 Bacterial dihydropteroate synthase inhibitor
Trimethoprim
Phase 3 Bacterial dihydrofolate reductase inhibitor
Tromethamine
Phase 3 Unknown
Mannitol
Phase 3 Unknown
Folic acid
Phase 3
Abamectin
Phase 3
Zinc ion
Phase 3
Artemisin
Phase 3
Cipargamin
Phase 2 P-type ATPase inhibitor

Showing the 30 furthest along of 69 in trials.

How Its Trials Ended

1,283 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 463 whose ending is known, 67% met their primary endpoint, 13% missed it and 21% stopped early.

  • Completed, result not reported59046%
  • Met its primary endpoint30824%
  • Ongoing1199%
  • Status unknown1119%
  • Stopped: other or unclear625%
  • Missed its primary endpoint605%
  • Stopped: lack of efficacy101%
  • Stopped: sponsor or business decision81%
  • Stopped: enrollment or feasibility71%
  • Stopped: safety50%
  • Stopped: funding30%

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 26
May 26, 2020ArtesunateArtesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe…Amivas Inc.Approved
Jul 20, 2018KrintafelKRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are…GlaxoSmithKline Intellectual Property Development Ltd. EnglandApproved
Apr 7, 2009CoartemTreatment of malaria in patients of 5 kg bodyweight or above with acute, uncomplicated malaria due to Plasmodium falciparum or mixed…Novartis PharmaceuticalsApproved
Aug 12, 2005Quinine SulfateTreatment of uncomplicated Plasmodium falciparum malariaAR Holding Company, Inc.Approved
Jul 24, 1992HalfanTreatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium…SmithKline Beecham PharmaceuticalsApproved
Oct 20, 2026Dual plasmepsin inhibitor against plasmepsin IX and…Treatment of malariaMerck, Sharp & Dohme LLCDesignated
Jun 20, 20253S,4R,8R,9S,10S)-10-…Treatment of malariaEisai Inc.Designated
Aug 15, 2022Ganaplacide and Lumefantrine fixed-dose combinationTreatment of MalariaNovartis Pharmaceuticals CorporationDesignated
Dec 14, 2021(R)-N2-(4-cyclopropyl-5-fluoro-6-methylpyridin-2-yl)-N4-(1,…Treatment of malariaCadila Healthcare LimitedDesignated
May 1, 2020CipargaminTreatment of malariaNovartis Pharmaceuticals CorporationDesignated
Feb 11, 2020Pyronaridine tetraphosphateTreatment of MalariaCollaborations Pharmaceuticals, Inc.Designated
Mar 15, 2019MeplazumabTreatment of malariaJiangsu Pacific-Meinuoke Bio-pharmaceutical Co., Ltd.Designated
Sep 27, 2018Fixed dose combination of pyronaridine tetraphosphate and…Treatment of malariaShin Poong Pharmaceutical Co., Ltd.Designated
Sep 5, 2017ArtesunateTreatment of malariaGuilin Pharmaceutical Co., Ltd.Designated
Aug 18, 20172-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-¿{6}-sulfan…Treatment of malariaPaul Maher, MDDesignated

Medicines Authorised in the EU

Newest first
Nov 22, 2021Artesunate AmivasArtesunate · orphanAmivas Ireland LtdEMA ↗
Oct 27, 2011EurartesimPiperaquine tetraphosphate;artenimolAlfasigma S.p.A.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.